Welcome to our dedicated page for Theralase Technologies news (Ticker: TLTFF), a resource for investors and traders seeking the latest updates and insights on Theralase Technologies stock.
Theralase Technologies Inc. (TLTFF) is a clinical stage pharmaceutical company whose news flow centers on the development of light, radiation, sound and drug-activated small molecule compounds for the destruction of cancers, bacteria and viruses. Company announcements frequently highlight progress in its oncology and antiviral programs, financing activities and collaborations with partners.
Investors following TLTFF news can expect regular updates on Theralase’s Phase II clinical study in Bacillus Calmette-Guérin-unresponsive non-muscle invasive bladder cancer carcinoma in situ, where the company is clinically investigating light-activated Ruvidar. Releases have included interim clinical response data, enrollment status and timelines for data lock and regulatory submissions as described by the company.
News items also cover preclinical research, such as studies of radiation-activated Rutherrin in multiple cancer models and peer-reviewed data on Ruvidar as an antiviral candidate against Herpes Simplex Virus Type 1. These updates summarize scientific findings, mechanisms under investigation and potential implications for future development, as presented by Theralase and collaborating researchers.
From a capital markets perspective, Theralase’s news includes details of non-brokered private placements, warrant extensions and short-term loans, along with the intended use of proceeds for clinical studies, development work and working capital. The company also issues reminders and summaries for investor conference calls where management discusses financial statements and operational milestones.
This TLTFF news page aggregates these disclosures so readers can review company-stated clinical, scientific and financing developments in one place and monitor how Theralase describes the evolution of its small molecule programs over time.
Theralase Technologies Inc. (TSXV: TLT, OTCQB: TLTFF) has released its audited annual financial statements for 2022. The company experienced a 46% increase in total revenue to $1.14 million, fueled by recovery from the COVID-19 pandemic. Gross margin rose to 55% of revenue, compared to 40% in 2021. Selling and administrative expenses declined by 17% and 18%, respectively. However, net research and development expenses surged 46% to $4.28 million, resulting in a net loss of $5.24 million for the year. The company continues to progress in its Phase II clinical study for NMIBC treatments, reporting interim data indicating a 54% complete response rate at 90 days. Theralase was also recognized in the 2023 Venture 50™ for its performance in the Clean Technology and Life Sciences sector.
FAQ
What is the current stock price of Theralase Technologies (TLTFF)?
What is the market cap of Theralase Technologies (TLTFF)?
